Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink
Key Takeaways |
|
Introduction
Reports of a Chinese "cancer cure" appear regularly, from new cell therapies to experimental virus treatments. Patients and families abroad want to know which of these are real, and which they can actually reach.
The short answer: China has not cured cancer as a whole, and no country has. What China has done is approve a fast-growing set of advanced treatments, several of them world firsts, that are open to international patients today. Others remain in clinical trials or the laboratory.
This guide sorts each major breakthrough by where it stands in 2026, explains what "cure" means in cancer care, and sets out costs, eligibility and how international patients can access treatment in China.
What Does a Cancer "Cure" Mean?
Oncologists rarely use the word cure for advanced cancer. They use more precise terms:
Complete remission: no detectable cancer on scans and tests after treatment.
Long-term remission: the cancer stays undetectable for years. Many doctors consider a patient effectively cured after about five years without relapse.
Disease control: the tumour stops growing or shrinks, even if it does not disappear.
Survival benefit: a treatment helps patients live longer than the previous standard.
China's newest treatments sit at different points on this scale. Blood cancer CAR-T can produce long-term remission in some patients. Satri-cel and ivonescimab extend survival and control disease in patients with few other options. The sections below show which is which.
China's Cancer Breakthroughs: What Is Approved and What Is Available
Breakthrough | Developer | Status in October 2026 | Open to international patients? |
Satri-cel, CAR-T for Claudin18.2-positive stomach cancer | CARsgen Therapeutics | Approved nationwide (NMPA), June 2026 | Yes, after biomarker testing at an approved hospital |
Ivonescimab, PD-1/VEGF bispecific antibody for lung cancer | Akeso | Approved nationwide, 2024 and 2025 | Yes, prescribed after an oncology consultation |
CAR-T for lymphoma, leukaemia and multiple myeloma | Several Chinese and joint-venture makers | Approved since 2021 | Yes, since 2021 |
Personalised dendritic cell (DC) cancer vaccine | Boao Lecheng pilot zone hospital | Special access in Hainan | Yes, in the Boao Lecheng pilot zone |
NDV-GT engineered virus therapy | Guangxi Medical University | Early clinical study, 20 patients | Not yet; research enrolment only |
CAR-iNK cells from cord blood stem cells | Chinese Academy of Sciences | Laboratory and mouse studies | No |
Table of Content
Approved Now: Treatments International Patients Can Access
Satri-cel: The World's First CAR-T for a Solid Tumour
On June 22, 2026, China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel), developed by Shanghai-based CARsgen Therapeutics. No regulator anywhere had approved a CAR-T therapy for a solid tumour before.
How it works: a patient's own T cells are collected, engineered to recognise Claudin18.2, a protein found on many stomach cancer cells, then infused back to attack the tumour.
Who it is for: adults with Claudin18.2-positive, HER2-negative advanced stomach or gastroesophageal junction cancer whose disease has progressed after at least two prior lines of treatment.
Result: in the randomised phase 2 trial behind the approval, published in The Lancet, median progression-free survival was 3.25 months with satri-cel versus 1.77 months with the doctor's choice of treatment. Median overall survival was 7.92 months versus 5.49 months, in patients who had largely run out of options.
Price: CARsgen priced satri-cel at 990,000 yuan (about US$146,500) per infusion.
F
ull guides: CAR-T for Stomach Cancer in China and Satri-cel vs Chemotherapy.
Ivonescimab: The Lung Cancer Drug That Beat Keytruda
Ivonescimab, from Akeso, is the world's first approved antibody that blocks both PD-1 (to re-activate the immune system) and VEGF (to cut the tumour's blood supply).
May 2024: approved with chemotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) after targeted therapy stops working.
April 2025: approved on its own as first-line treatment for PD-L1-positive advanced NSCLC without EGFR or ALK mutations.
Result: in the HARMONi-2 trial, the first head-to-head win against pembrolizumab (Keytruda), median progression-free survival was 11.1 months versus 5.8 months. In September 2026, updated data showed median overall survival of 30.8 months versus 22.6 months.
CAR-T for Blood Cancers: Open to Foreigners Since 2021
China approved its first CAR-T therapies in 2021 and now offers several products for relapsed or refractory lymphoma, leukaemia and multiple myeloma. China also runs more CAR-T clinical trials than any other country.
Three advantages draw international patients: price, speed and support. The Wall Street Journal reported in 2026 that CAR-T costs about US$150,000 to US$230,000 in China, against US$550,000 to US$850,000 in the US. Laboratories near Shanghai can produce a patient's cells in days, while the process often takes three weeks or more in the US.
Case study: New Zealand patients in Shanghai. A man from New Zealand with non-Hodgkin lymphoma travelled to Shanghai for CAR-T because treatment there was more affordable. A second New Zealander made the same trip because the solid-tumour CAR-T he needed was then available only in China. Shanghai doctors told the WSJ that most of their international CAR-T patients are now free of cancer, and that enquiries from Southeast Asia, Canada, Europe and the US are rising.
Full case study: 9,000 Kilometres: How a New Zealand Patient Became the First International Patient to Complete Solid-Tumor CAR-T Treatment in China.
Special Access: Personalised Cancer Vaccine in Boao Lecheng
Hainan's Boao Lecheng International Medical Tourism Pilot Zone lets approved hospitals use selected new treatments before nationwide approval. One is a personalised dendritic cell (DC) vaccine built from the patient's own tumour antigens, for eligible solid tumours, at about US$22,300 per injection.
Full guide: China Cancer Vaccine 2026.
Which Chinese Cancer Treatments Are Still in Clinical Research?
Engineered Virus Therapy (NDV-GT) for Advanced Solid Tumours
Professor Zhao Yongxiang's team at Guangxi Medical University inserted a pig gene into Newcastle disease virus. Infected tumour cells display a pig sugar molecule, so the immune system attacks them the way it would reject a pig organ. The study, published in Cell in January 2025, treated 20 patients with refractory, metastatic cancers. News reports said about 90% saw tumour growth stop or shrink, and one cervical cancer patient was declared clinically cured.
Status: a small early study. The therapy is not approved, and no route for international patients has been published.
Lab-Grown CAR-NK Cells for Leukaemia
A Chinese Academy of Sciences team led by Professor Wang Jinyong grew natural killer (NK) cells from cord blood stem cells. One stem cell produced up to 14 million NK cells, or 7.6 million CAR-equipped ones, which shrank leukaemia in mice. The method could make cell therapy far cheaper.
Status: laboratory and animal research only. Human trials have not been reported.
Why China Is Moving So Fast
More approvals: China's NMPA approved 94 novel cancer drugs from 2020 to 2025, against 87 by the US FDA, and out-approved the FDA in each year from 2023 to 2025.
A deep pipeline: cancer accounted for 37.5% of China's innovative drug trials in 2025, and cell and gene therapy trials grew nearly 30%.
Scale: China diagnoses about 4.8 million new cancer cases a year, so trials enrol quickly and hospitals see high volumes. Its five-year cancer survival rate rose from 40.5% in 2015 to 43.7% in 2022.
The picture is not one-sided. The FDA still approves more first-in-class drugs and reviews them faster, and most Chinese approvals are for patients who have already tried standard treatment
How Much Does Advanced Cancer Treatment Cost in China?
Treatment | Published or reported price in China |
Satri-cel (stomach cancer CAR-T) | 990,000 yuan (about US$146,500) per infusion |
CAR-T for blood cancers | About US$150,000 to US$230,000 (vs US$550,000 to US$850,000 in the US) |
Personalised DC cancer vaccine (Boao Lecheng) | About US$22,300 per injection |
Prices usually exclude testing, hospital stay, travel and a caregiver's costs. Patients should request a written, itemised quote before travelling.
Who Is Eligible?
Option | Best suited for |
Satri-cel | Advanced Claudin18.2-positive, HER2-negative stomach or GEJ cancer after at least two prior treatment lines |
Ivonescimab | Advanced NSCLC: first-line if PD-L1-positive without EGFR/ALK mutations; with chemotherapy if EGFR-mutated after targeted therapy |
Blood cancer CAR-T | Relapsed or refractory lymphoma, leukaemia or multiple myeloma after standard treatment |
DC vaccine (Boao) | Eligible solid tumours during post-surgery care or systemic therapy |
How International Patients Can Access Treatment
Through ChinaCureLink (dedicated international patient pathway): after a free advisory call, ChinaCureLink compares up to three suitable hospitals or specialists for the patient's cancer type and stage, then coordinates records, translation, the video second opinion and travel.
Directly through a hospital's international department: the patient sends records, arranges a consultation and an invitation letter for an S2 medical visa, and manages translation and logistics independently.
Through a clinical trial: some research treatments enrol international patients. See How to Join a Cancer Clinical Trial in China.
What to Know Before Travelling
Choose approved or regulated treatment. Avoid clinics selling unapproved "cancer cures". Approved drugs, NMPA-approved CAR-T and Boao Lecheng special-access programmes are regulated routes.
Bring complete records: pathology, recent scans, biomarker results (such as Claudin18.2, HER2, PD-L1, EGFR) and a treatment history.
Plan time: CAR-T usually needs several weeks in China for cell collection, infusion and monitoring.
Keep the home doctor involved for follow-up after returning.
Arrange the visa early: see the China Medical Visa Guide and Travelling to China for Medical Treatment.
How ChinaCureLink Can Help
The fastest way to reach China's newest cancer treatments is to contact Chinese hospitals directly through a trusted facilitator, so the patient's records reach the right specialists before any travel.
ChinaCureLink represents the patient, not any specific hospital. There is no fee to apply to hospitals, only a moderate fee for on-site support in China. After a free advisory call, ChinaCureLink identifies and compares up to three suitable hospitals or specialists. The patient chooses a preferred option and joins a video second opinion with that specialist. If the patient proceeds, ChinaCureLink coordinates the appointment, records and translation, hospital communication, treatment planning, travel and in-China support. More on how ChinaCureLink matches each case.
Questions about which treatment in China fits a diagnosis? Chat with the ChinaCureLink team on WhatsApp.
You may also like:
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Has China Found a Cure for Cancer?
No single cure exists, in China or anywhere. China has approved several world-first treatments, including satri-cel, the first CAR-T for a solid tumour (June 2026), and ivonescimab, which outperformed Keytruda in lung cancer. Some blood cancer patients treated with CAR-T in China remain cancer-free for years.
Is the NDV-GT Virus Therapy Available to Patients?
Not yet. The NDV-GT virus therapy from Guangxi Medical University, which makes tumours resemble pig tissue so the immune system attacks them, has been tested in 20 patients in an early study. It is not approved, and no international enrolment route has been published.
What Is the World's First CAR-T for Solid Tumours?
Satri-cel, approved in China in June 2026 for Claudin18.2-positive, HER2-negative advanced stomach and gastroesophageal junction cancer after at least two prior treatments.
Can Foreigners Get CAR-T Therapy in China?
Yes. China has allowed international patients to receive CAR-T since 2021, and patients from New Zealand, Australia and the US have travelled to Shanghai for it.
How Much Does Cancer Treatment Cost in China?
Blood cancer CAR-T costs about US$150,000 to US$230,000, satri-cel is priced at 990,000 yuan (about US$146,500) per infusion, and the Boao Lecheng DC vaccine about US$22,300 per injection. Travel and hospital stays are extra.
Is It Safe to Travel to China for Cancer Treatment?
It is safest when the treatment is approved by China's NMPA or offered under Boao Lecheng's regulated special-access rules, at a major hospital, after a specialist has reviewed the patient's records. Clinics promising a guaranteed cure should be avoided.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
CARsgen Therapeutics via OncLive. China's NMPA approves first CAR T-cell therapy for CLDN18.2+, HER2- advanced gastric/GEJ adenocarcinoma. June 22, 2026.
The Medicine Maker. World's first solid tumor CAR-T approved in China. June 2026.
Caixin Global. China approves world's first CAR-T therapy for solid tumors. June 24, 2026.
Akeso via BioSpace. Ivonescimab receives NMPA approval for first-line treatment of PD-L1-positive NSCLC. April 25, 2025.
News-Medical. Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC. September 14, 2026.
The Wall Street Journal. Patients are flying to China for the latest cancer treatment. 2026.
ThePrint. Cancer patients from US, Europe are heading to China for treatment. 2026.
South China Morning Post. Chinese scientists turn tumours into 'pork' in radical cancer treatment. March 17, 2025.
Anadolu Agency. Chinese scientists develop cancer treatment that makes tumors mimic 'pork'. March 18, 2025.
Chinese Academy of Sciences via ScienceDaily. One stem cell generates 14 million tumor-killing NK cells. February 17, 2026.
Friends of Cancer Research. China has outpaced the US in novel cancer drug approvals since 2023. July 2026.
Cisema. CDE 2025 annual report on new drug clinical trials in China. 2026.
National Cancer Center of China via PMC. Cancer incidence and mortality in China, 2022. 2024.
China Daily. China promotes early detection, treatment to fight tumors. April 2024.
